REGENXBIO To Participate In Chardan's 8Th Annual Genetic Medicines Conference
Date
9/23/2024 4:16:21 PM
(MENAFN- PR Newswire)
ROCKVILLE, Md., Sept. 23, 2024 /PRNewswire/ --
REGENXBIO Inc. (Nasdaq: RGNX ) today announced it will participate in Chardan's 8th Annual Genetic Medicines conference on Monday, September 30, 2024.
Chardan's 8th Annual Genetic Medicines Conference
Fireside Chat: Monday, September 30, 2024 at 8:30 a.m. ET
Location: New York, NY
A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at . An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit .
Contacts:
Dana Cormack
Corporate Communications
[email protected]
Investors:
George E. MacDougall
Investor Relations
[email protected]
SOURCE REGENXBIO Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN23092024003732001241ID1108706166
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.